Akorn (AKRX) gets FDA approval for a generic version of vancomycin, an antibiotic used against...


Akorn (AKRX) gets FDA approval for a generic version of vancomycin, an antibiotic used against life-threatening infections. It expects to market the drug in the first half of 2009, and sees annual sales of $150M. Shares of the $175M firm are up 28% premarket to $2.50.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs